Edition:
United States

ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

34.33USD
28 Apr 2017
Change (% chg)

$0.50 (+1.48%)
Prev Close
$33.83
Open
$33.87
Day's High
$34.39
Day's Low
$33.50
Volume
1,127,295
Avg. Vol
2,119,287
52-wk High
$42.49
52-wk Low
$20.68

Latest Key Developments (Source: Significant Developments)

Acadia Pharmaceuticals Q4 loss per share $0.65
Tuesday, 28 Feb 2017 04:05pm EST 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals reports financial results for the fourth quarter and year ended december 31, 2016 . Q4 loss per share $0.65 .Q4 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S.  Full Article

Acadia Pharmaceuticals announces positive top-line results from phase ii study of pimavanserin for alzheimer's disease psychosis
Tuesday, 20 Dec 2016 07:00am EST 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals announces positive top-line results from phase ii study of pimavanserin for alzheimer's disease psychosis . Pimavanserin met primary endpoint showing a statistically significant reduction in psychosis versus placebo .Pimavanserin was generally well tolerated.  Full Article

Acadia Pharmaceuticals initiates phase II trial of Pimavanserin
Tuesday, 15 Nov 2016 09:00am EST 

Acadia Pharmaceuticals Inc :Acadia Pharmaceuticals initiates phase II trial of Pimavanserin for adjunctive treatment in patients with negative symptoms of schizophrenia.  Full Article

Acadia Pharmaceuticals announces proposed public offering of common stock
Monday, 8 Aug 2016 04:01pm EDT 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals announces proposed public offering of common stock .Acadia Pharmaceuticals Inc says that it intends to offer and sell, subject to market and other conditions, $200 million of its common stock.  Full Article

Acadia Pharmaceuticals reports Q2 2016 financial results
Thursday, 4 Aug 2016 04:05pm EDT 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals reports second quarter 2016 financial results .Qtrly loss per share $0.63.  Full Article

UK's CMA could accept undertakings on Acadia's Priory Group deal
Thursday, 28 Jul 2016 07:09am EDT 

UK's CMA : To look at Acadia's undertakings offer in relation to acquisition of Priory Group No 1 Ltd in detail . Considers that undertaking offered, or a modified version of it, might be accepted .Now has until 23 September to decide whether to accept undertaking, with possibility to extend this timeframe to 18 november.  Full Article

ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
Tuesday, 5 Jan 2016 04:05pm EST 

ACADIA Pharmaceuticals Inc:t intends to offer and sell, subject to market and other conditions, $300,000,000 of shares of its common stock in an underwritten public offering.There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.BofA Merrill Lynch and J.P. Morgan Securities LLC are acting as the joint book-running managers for the offering.ACADIA intends to grant the underwriters a 30-day option to purchase an additional $45,000,000 of shares of its common stock.  Full Article

ACADIA Pharmaceuticals Inc Appoints Steve Davis as Chief Executive Officer
Thursday, 3 Sep 2015 07:01am EDT 

ACADIA Pharmaceuticals Inc:Board of Directors has appointed Steve Davis as President and Chief Executive Officer.Davis has been serving as ACADIA's Interim Chief Executive Officer since March 2015.Davis has also been appointed to the ACADIA Board of Directors.  Full Article

ACADIA Pharmaceuticals submits new drug application for NUPLAZID for the Treatment of Parkinson's Disease Psychosis
Thursday, 3 Sep 2015 07:00am EDT 

ACADIA Pharmaceuticals Inc:Announces it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease.  Full Article

More From Around the Web

BRIEF-Acadia Pharmaceuticals Q4 loss per share $0.65

* Acadia Pharmaceuticals reports financial results for the fourth quarter and year ended december 31, 2016